Vaccination Against High Risk Breast Cancer Using Tumor Derived Heat Shock Protein 70
Stopped early · Phase 1/Phase 2
Conditions studied: Breast Neoplasms
In brief
Description: The trial is designed to determine the response of the immune system of patients with breast cancer to a vaccine made from their own tumor. Researchers believe that this particular vaccine, which is made from purified heat shock proteins taken from each patient's tumor, might alert the body's immune system to recognize and attack invading cancer. To be considered potentially eligible for this study you must be a high risk breast cancer patient and have a tumor that can be removed surgically. Length/Duration: Vaccinations are administered weekly for six weeks. Follow up visits to the clinic are every three months for two years, then every six months thereafter.
Key facts
- Study ID
- NCT00027131
- Run by
- UConn Health
- People needed
- 15
- Starts
- 2000-12-01
- Expected to finish
- 2002-10-01
- Last updated by the study team
- 2008-10-08
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
Where it is running
- University of Connecticut Health Center — Farmington, Connecticut, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.